Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Kerver, E.D."'
Autor:
Versteijne, E., Suker, M., Groothuis, K., Akkermans-Vogelaar, J.M., Besselink, M.G., Bonsing, B.A., Buijsen, J., Busch, O.R., Creemers, G.J.M., Dam, R.M. van, Eskens, F.A.L.M., Festen, S., Groot, J.W.B. de, Koerkamp, B.G., Hingh, I.H. de, Homs, M.Y.V., Hooft, J.E. van, Kerver, E.D., Luelmo, S.A.C., Neelis, K.J., Nuyttens, J., Paardekooper, G.M.R.M., Patijn, G.A., Sangen, M.J.C. van der, Vos-Geelen, J. de, Wilmink, J.W., Zwinderman, A.H., Punt, C.J., Eijck, C.H. van, Tienhoven, G. van, Dutch Pancreatic Canc Grp
Publikováno v:
Journal of Clinical Oncology, 38(16), 1763-1773. AMER SOC CLINICAL ONCOLOGY
Journal of clinical oncology, 38(16), 1763-1773. American Society of Clinical Oncology
Journal of Clinical Oncology, 38(16), 1763-1773. American Society of Clinical Oncology
J Clin Oncol
Journal of clinical oncology, 38(16), 1763-1773. American Society of Clinical Oncology
Journal of Clinical Oncology, 38(16), 1763-1773. American Society of Clinical Oncology
J Clin Oncol
PURPOSE Preoperative chemoradiotherapy may improve the radical resection rate for resectable or borderline resectable pancreatic cancer, but the overall benefit is unproven. PATIENTS AND METHODS In this randomized phase III trial in 16 centers, patie
Autor:
Badrising, S.K., Noort, V. van der, Hamberg, P., Coenen, J.L.L.M., Aarts, M.J., Oort, I.M. van, Eertwegh, A.J.M. van den, M. los, Berg, H.P. van den, Gelderblom, H., Vrijaldenhoven, S., Kerver, E.D., Voorthuizen, T. van, Jong, I.J. de, Haanen, J.B., Bergman, A.M., Dutch Uro-Oncol Study Grp DUOS
Publikováno v:
Oncology : journal of clinical and experimental cancer research, 91(5), 267-273. KARGER
Oncology, 91(5), 267-273. S. Karger AG
Badrising, S K, van der Noort, V, Hamberg, P, Coenen, J L L M, Aarts, M J, van Oort, I M, van den Eertwegh, A J M, Los, M, van den Berg, H P, Gelderblom, H, Vrijaldenhoven, S, Kerver, E D, van Voorthuizen, T, de Jong, I J, Haanen, J B, Bergman, A M & Dutch Uro-Oncology Study Group (DUOS) 2016, ' Enzalutamide as a Fourth-or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer ', Oncology, vol. 91, no. 5, pp. 267-273 . https://doi.org/10.1159/000448219
Oncology (Basel: 1948), 91, 5, pp. 267-273
Oncology (Basel: 1948), 91, 267-273
Oncology, 91(5), 267-273. Karger
Oncology, 91(5), 267-273
Oncology, 91(5), 267-273. S. Karger AG
Badrising, S K, van der Noort, V, Hamberg, P, Coenen, J L L M, Aarts, M J, van Oort, I M, van den Eertwegh, A J M, Los, M, van den Berg, H P, Gelderblom, H, Vrijaldenhoven, S, Kerver, E D, van Voorthuizen, T, de Jong, I J, Haanen, J B, Bergman, A M & Dutch Uro-Oncology Study Group (DUOS) 2016, ' Enzalutamide as a Fourth-or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer ', Oncology, vol. 91, no. 5, pp. 267-273 . https://doi.org/10.1159/000448219
Oncology (Basel: 1948), 91, 5, pp. 267-273
Oncology (Basel: 1948), 91, 267-273
Oncology, 91(5), 267-273. Karger
Oncology, 91(5), 267-273
Objective: To evaluate the efficacy of enzalutamide (Enz) as fourth- or fifth-line treatment in men with metastasized castration-resistant prostate cancer (mCRPC), by analyzing a retrospective cohort of heavily pretreated patients. Methods: We evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dca8b6195ac05ce8160daf10d82ca2d8
https://doi.org/10.1159/000448219
https://doi.org/10.1159/000448219